| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 4388.9 | 4336.0 | 4295.5 |
| Other income | 34.5 | 54.5 | 93.0 |
| Total income | 4423.4 | 4390.5 | 4388.5 |
| Profit before exceptional items & tax | 61.5 | 141.1 | 183.2 |
| Exceptional items | -6.7 | -13.5 | -11.9 |
| Profit before tax | 54.8 | 127.6 | 171.3 |
| Net profit | 56.7 | 136.8 | 132.8 |
| Operating margin | 1.2% | 2.9% | 3.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -57.30% |
|---|---|
| Net profit, quarter on quarter | -58.60% |
| Revenue, year on year | +2.20% |
| Operating profit, year on year | -70.10% |
| Operating profit, quarter on quarter | -68.80% |
BSE results filing, NSE: BIOCON. Figures extracted from the filing.
Biocon Ltd: key numbers
- Share price
- ₹345.10
- Market cap
- ₹56,241 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 113.5×Sector 41.3×
- Promoter holding
- 44.68%+0.00% QoQ
- FII holding
- 8.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biocon Ltd
All →Biocon Investor Presentation: Key Takeaways
Q2 FY27 revenue from operations ₹4,389 Cr (+2% YoY), EBITDA ₹865 Cr (20% margin vs 22%), reported PAT ₹41 Cr (−52% YoY). Management expects a stronger H2.
Biocon Results Update
Biocon reported Q2FY27 consolidated total income of ₹4,423 crore with EBITDA at ₹865 crore. Net profit was ₹41 crore as Biopharma revenue grew 5% YoY.
Biocon Board Meeting Date
Biocon schedules a November 4, 2026 board meeting for Q2 FY27 unaudited results, plus an earnings call. Trading window stays closed until November 6, 2026.
Biocon Business Update
Biocon signed a licence agreement with Janssen to commercialise biosimilar Yesintek in nine more markets, including Australia, Brazil and China. No deal value is disclosed.
Biocon Other Announcement
Biocon Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing details the distribution of equity shares among various stakeholder categories.
Biocon Partnership
Biocon entered a global patent settlement and license agreement with Genentech, securing early launch dates for its biosimilar Pebrilzo® (bPertuzumab) across key global markets.
- From
- Genentech